Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

First Posted Date
2004-06-28
Last Posted Date
2011-11-30
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00005854
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 1 locations

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Phase 1
Conditions
First Posted Date
2004-06-17
Last Posted Date
2013-08-07
Lead Sponsor
University of California, Davis
Target Recruit Count
18
Registration Number
NCT00003920
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California Davis Medical Center, Sacramento, California, United States

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Phase 2
Completed
Conditions
First Posted Date
2004-06-16
Last Posted Date
2014-07-24
Lead Sponsor
Children's Oncology Group
Registration Number
NCT00002785
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital Los Angeles, Los Angeles, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Ireland Cancer Center, Cleveland, Ohio, United States

and more 30 locations

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2004-06-11
Last Posted Date
2019-11-27
Lead Sponsor
Alliance for Clinical Trials in Oncology
Registration Number
NCT00085449
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 21 locations

Bone Marrow Transplantation in Treating Patients With Leukemia

First Posted Date
2004-06-09
Last Posted Date
2020-01-03
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Registration Number
NCT00006451
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

First Posted Date
2004-06-08
Last Posted Date
2012-12-11
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Registration Number
NCT00005641
Locations
๐Ÿ‡บ๐Ÿ‡ธ

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Phase 2
Completed
Conditions
First Posted Date
2004-05-24
Last Posted Date
2012-08-07
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
280
Registration Number
NCT00002547
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

First Posted Date
2004-05-24
Last Posted Date
2010-02-24
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
19
Registration Number
NCT00003187
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of South Carolina School of Medicine, Columbia, South Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States

and more 10 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath